COMPANY PROFILE

Parabilis Medicines

Explore full profile

Developing helical peptide therapeutics targeting hard-to-drug disease proteins

Cambridge, United StatesFounded 2016Biotech & Life Sciences

Valuation $2.5–5B Last recorded · 2026

Headcount 100–500 Current team size

Total funding $500M–1B Disclosed equity funding

Unlock exact values

About Parabilis Medicines

Parabilis Medicines, (formerly know as Fog Pharmaceuticals) is a dynamic startup operating in the pharmaceutical industry, specifically in the field of drug discovery. The company's primary focus is on developing a new class of drugs, known as Helicon therapeutics, to target previously untreatable diseases. Their approach integrates advanced technologies to speed up and scale the process of drug discovery, making it more efficient and effective.

The company's primary market is the healthcare sector, with a particular emphasis on treating cancer. Their lead program, FOG-001, is a first-in-class TCF-blocking β-catenin inhibitor, which is currently undergoing a Phase 1/2 clinical trial. This drug is designed to target the most common yet elusive drivers of cancer, making it a potentially groundbreaking treatment.

FogPharma operates on a business model that combines research, development, and commercialization of pharmaceutical products. They generate revenue through the successful development and sale of these innovative drugs. Additionally, they also likely seek funding from investors who are interested in the pharmaceutical and biotech sector.

The company values learning and collaboration, and is constantly seeking to push the boundaries of science. They are on a mission to shape the future of precision medicine and are looking for passionate individuals to join their team.

In summary, FogPharma is a promising startup that combines cutting-edge technology with innovative science to develop novel treatments for previously untreatable diseases.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Cambridge, United States
Employees: 195
Open positions: 19
Dealroom signal: 87.5/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Medical Research, Oncology, Medical & Healthcare, Precision Medicine, Verified Unicorns and $1B Exits, Biotech and Pharma, Woman Founder
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

9 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
PRIVATE PLACEMENT NON VCOther financing	Jun 2026	$75M	—	Regeneron Pharmaceuticals	↗
IPOOther financing	Jun 2026	$670M	$2.4B	Undisclosed	↗

Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Growth	Margin
2026	—	—
2025	—	—
2024	—	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Parabilis Medicines website traffic

Latest recorded traffic for Parabilis Medicines is 17K monthly website visits, up 88.9% over the last three months. Parabilis Medicines's team grew 8.9% over the past year.

Latest monthly visits17K 3-month web change+88.9% 1-year team growth+8.9%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Senior Director, Clinical Operations NewCambridge, Massachusetts, United States, Northern America, Americas · Other · Sep 5, 2026 In Vivo Study Specialist CambridgeCambridge, Massachusetts, United States, Northern America, Americas · Other · Sep 5, 2026 Senior Manager, Regulatory Operations New30 Acorn Park Dr, Cambridge, MA 02140, USA · Legal · Aug 24, 2026 Associate Director, Regulatory Affairs New30 Acorn Park Dr, Cambridge, MA 02140, USA · Other · Aug 24, 2026 Senior Director, Medicinal Chemistry Design CambridgeCambridge, United Kingdom, Northern Europe, Europe · Design · Aug 24, 2026 Director, Corporate Attorney New CambridgeCambridge, United Kingdom, Northern Europe, Europe · Legal · Aug 19, 2026 Senior Director, Investor Relations New CambridgeCambridge, United Kingdom, Northern Europe, Europe · Finance · Aug 19, 2026 Senior Director, Safety Scientist NewCambridge, United Kingdom, Northern Europe, Europe · Other · Aug 19, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HTHalda TherapeuticsPrecision oncology therapies targeting cancer via RIPTAC™ chimera	New Haven, United States	Acquired	40	$126M	$3B
YTYsotope TheranosticsTargeted radiopharmaceuticals for precision oncology	Madrid, Spain	Operational
BIBioNTechDevelops personalized immunotherapies with a focus on cancer medicine	Mainz, Germany	Operational
OWOwkinCollaborative research platform and unique AI drug development solutions that make precision medicine a reality	Paris, France	Operational
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
MBMyricx BioNovel antibody-drug conjugate payloads for cancer treatment	London, United Kingdom	Acquired
MIMicrometBiopharmaceutical company focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases	Carlsbad, United States	Acquired